Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

New Targeted Therapy Duo Provides Advantages in BRAF-Mutant Melanoma

March 4th 2019

Keith T. Flaherty, MD, discussed the distinguishing features of the combination of encorafenib with binimetinib as well as some next steps, including the question of whether the regimen eventually could move to the adjuvant setting.

Dr. Sullivan on Considerations for Treatment in Metastatic Melanoma

February 28th 2019

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses considerations for initial treatment of patients with metastatic melanoma.

Diet May Impact Response to Immunotherapy in Patients With Melanoma

February 28th 2019

Select patients with melanoma who consume a diet rich in fiber could see an improved response to treatment with immunotherapy.

Dr. Ribas on Immune-Related Adverse Events in Melanoma

February 27th 2019

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.

Dr. Tawbi on Unmet Needs in Melanoma

February 22nd 2019

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses unmet needs in melanoma.

Dr. Weber on FDA Approval of Pembrolizumab for Stage III Melanoma

February 19th 2019

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone's Perlmutter Cancer Center, a 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrolizumab for stage III melanoma.

FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma

February 19th 2019

The FDA has approved the PD-1 inhibitor pembrolizumab for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection.

Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma

January 30th 2019

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.

Dr. Ribas on Combination Immunotherapy and Radiation in Melanoma

January 22nd 2019

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses the potential for combination immunotherapy and radiation in the treatment of patients with melanoma.

Pembrolizumab Granted 5 Additional Approvals in Japan

January 3rd 2019

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.

Dr. Hamid on the FDA Approval of Pembrolizumab in Merkel Cell Carcinoma

December 20th 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

FDA Approves Pembrolizumab in Merkel Cell Carcinoma

December 20th 2018

The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Adjuvant Pembrolizumab Approved in EU for Stage III Melanoma

December 18th 2018

The European Commission has approved pembrolizumab as an adjuvant treatment for patients with resected, stage III melanoma with lymph node involvement.

Cemiplimab Antitumor Activity in CSCC Sustained With Longer Follow-up

December 17th 2018

The monoclonal anti-PD-1 antibody cemiplimab continued to demonstrate considerable antitumor activity and durable responses in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma.

Dr. Tawbi on Evolving Treatment for Melanoma

December 3rd 2018

Hussein A. Tawbi, MD, PhD, associate professor of medicine, The University of Texas MD Anderson Cancer Center, discusses evolving treatment for patients with melanoma.

Dr. Hamid on the Inclusion of Patients With Brain Metastases on Melanoma Trials

December 1st 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the inclusion of patients with brain metastases on melanoma clinical trials.

Avelumab Continues to Show Value in JAVELIN Merkel 200 Analyses

December 1st 2018

In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported outcome endpoints.

Cemiplimab Explored in Advanced Basal Cell Carcinoma

November 30th 2018

An ongoing phase II study evaluating the PD-1 inhibitor cemiplimab in patients with basal cell carcinoma may prove efficacious based on its activity in other advanced malignancies.

Dr. Triebel on Novel Immunotherapy Combination in Melanoma

November 30th 2018

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immuntep Ltd, discusses a novel immunotherapy combination in melanoma.

Triplet Therapy With Novel PD-1 Inhibitor Holds Promise in Melanoma

November 28th 2018

The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresectable melanoma.